在药物耐药性慢性腹中使用克林诺提洛利特
B Palmieri1,2, M Vadalà1,2
1Network del Secondo Parere, Modena,Italia.
La Clinica terapeutica
|February 17, 2025
概括
这项研究发现,Xeoderm热粉有效地控制了慢性腹症状,改善了便的一致性并减少了不适. 当标准治疗失败时,它提供了一个安全的选择,提高了患者的生活质量.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 自然产品研究自然产品研究
背景情况:
- 慢性或复发性腹显著影响生活质量和心理健康.
- 标准的抗腹治疗可能不对所有患者有效.
- 石是一种天然矿物质,具有与胃肠道疾病相关的潜在吸附性.
研究的目的:
- 为了评估Xeoderm热粉的安全性和耐受性.
- 评估Xeoderm对慢性腹患者与健康相关的生活质量,肠道习惯和心理状况的疗效.
- 为了研究Xeoderm对与易怒肠综合征相关的症状的影响.
主要方法:
- 一组100名患有治疗不充分的慢性/复发性腹的患者接受了Xeoderm治疗12周.
- 患者自我报告的便频率,一致性 (布里斯托尔便形式尺度) 和症状强度.
- 在治疗前和治疗后评估了生活质量 (SF-12),刺激性肠综合征影响 (SGA) 和H. pylori状态.
主要成果:
- 泽奥德姆在控制常见便排放和改善便质量方面表现出有效性.
- 患者报告说,腹减少,不适减少,社会自信增加,特别是那些患有刺激性肠道疾病的患者.
- 观察到血液和便参数的变化表明Xeoderm治疗的生理影响.
结论:
- 泽奥德姆热粉显示出作为急性和慢性腹的安全和有效的症状治疗的前景.
- 它可以显著缓解症状,特别是当传统的抗腹疗法失败时.
- 这些发现表明,Xeoderm可能会调节结肠中的炎症过程,使粘膜循环正常化并减少.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140
01:21Drugs for Treatment of Constipation-Predominant IBS
129
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
129
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
177
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
177
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
170
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
170
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
135
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
135
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92